Drug reference
Treatment and prophylaxis of haemorrhage in patients with congenital factor VIII deficiency (haemophilia A) and factor VIII inhibitors | Treatment of haemorrhage in non-haemophiliac patients with acquired factor VIII inhibitors ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: (consult haematologist)
PDF page 143
Disseminated intravascular coagulation
PDF page 144
Risk of thrombosis. vaccination against hepatitis A and hepatitis B may be required Cardiovascular system
PDF page 144
Preparations with factor VIII inhibitor bypassing activity are prepared from human plasma.
PDF page 144
▶Common or very common Dizziness. headache. hypersensitivity. hypotension. skin reactions ▶Frequency not known Abdominal discomfort. anamnestic reaction. angioedema. chest discomfort. chills. cough. diarrhoea. disseminated intravascular coagulation. drowsiness. dyspnoea. embolism and thrombosis. fever. flushing. hypertension. ischaemic stroke. malaise. myocardial infarction. nausea. paraesthesia. respiratory disorders. restlessness. tachycardia. taste altered. vomiting
PDF page 144
There can be variation in the licensing of different medicines containing the same drug. Powder and solvent for solution for injection ▶FEIBA Imuno (Baxalta UK Ltd) Factor VIII inhibitor bypassing fraction 500 unit FEIBA 500unit powder and solvent for solution for injection vials | 1 vial P £390.00 Powder and solvent for solution for infusion ▶FEIBA Imuno (Baxalta UK Ltd) Factor VIII inhibitor bypassing fraction 1000 unit FEIBA 1,000unit powder and solvent for solution for infusion vials | 1 vial P £780.00 BLOOD AND RELATED PRODUCTS › PLASMA PRODUCTS
PDF page 144
(consult haematologist)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 143
